Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 1997

View Archived Issues

Novel antiangiogenic compounds from ADIR

Nissan Chemical discloses novel cardiovascular agents

Mitotix reports antiviral/anticancer antisense constructs

Novel human serine protease inhibitor for pancreatitis claimed by Incyte

T Cell Sciences describes anti-CETP vaccines

Anti-gp130 MAbs for inflammatory disorders and myeloma

Antidementia agents reported by Eisai

U.S. IND granted for Scotia's photodynamic drug

Pilocarpine TDS shows antiglaucoma activity in patients

University of Arizona researchers developing potential AD diagnostic

Lansoprazole equieffective to omeprazole in Dutch trial

Once-daily oral antibiotic from RPR cleared by FDA

Debate centers on the safety of coated aspirin

Immunomodulatory effects of ranitidine assessed in patient studies

Beacon signs Japanese licensing agreement for HIV and hepatitis tests

Company Profile: Cadila Pharmaceuticals

Hoechst establishes diagnostics company

Company Profile: Emisphere Technologies

Roche to acquire RPR consumer products

Crinone efficacy equal to that of higher doses of oral progesterone in IVF procedures

Novo Nordisk clear to market hGH product in U.S.

Osiris provides funds for clinical trial of hMSCs

Norian begins trial of Norian SRS in hip fractures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 22, 2025.
Coinfections and diversity paint the many shades of HIV cure
BioWorld
We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses...
Livzon’s IL-17A/F meets phase III endpoints in plaque psoriasis
BioWorld
Livzon Mabpharm Inc.’s anti-IL-17A/F monoclonal antibody, LZM-012, met the primary endpoint in a phase III trial in moderate to severe plaque psoriasis. Conducted...
Sino to acquire Lanova and pipeline for up to $950M
BioWorld Asia
Sino Biopharmaceutical Ltd. agreed to fully acquire Lanova Medicines Ltd. by buying an additional 95.09% stake in Lanova at a valuation of up to $950.92 million....